Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Alphamab announced PD-L1/CTLA-4 bispecific antibody KN046 will enter new Phase II clinical trial in combination with Pfizer's Inlyta® (axitinib) 2021-04-29 08:00
Alphamab Oncology Presented Clinical Data of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at AACR 2021 2021-04-13 08:15
Alphamab Oncology Reports Full Year 2020 Financial Results and Business Highlights 2021-03-23 23:08
Alphamab Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S. 2021-03-09 20:00
Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody 2020-06-10 08:40
Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer 2020-06-09 10:10
Alphamab Oncology, Simcere and 3D Medicines Announce Partnership to Develop and Commercialize Subcutaneous Injectable anti-PD-L1 Antibody for Oncology Indications in Mainland China 2020-03-30 19:00
Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance(R) (palbociclib) 2020-03-27 19:00
1 2 3 4